case_images: PMC11808248_01
case_images: Near-complete responses in an HR+/HER2-amplified metastatic breast cancer patient, initially with trastuzumab deruxtecan (HER2 IHC-positive) and then with a neratinib-based combination (IHC-negative). (A) The December 2022 PET result showed multiple lesions with FDG uptake in the liver parenchyma consistent with metastasis. (B) The PET scan in February 2023 after T-DXd treatment did not reveal any lesions with significant FDG uptake. (C) In the September 2023 PET result, liver parenchyma shows several lesions with FDG uptake in the right and left lobes, consistent with metastasis (arrows). (D) In the January 2024 PET examination, no lesions showing FDG uptake could be detected in these lobes. (E) Disease and treatment timeline.
case_images: fonc-14-1484750-g001.jpg
case_images: PMC11808248_01_fonc-14-1484750-g001.jpg
case_images: f1
case_images: CDKN2A. Considering that the patient exhausted all the standard treatment options as well as ERBB2 amplification with OE, we recommended trastuzumab deruxtecan (5.4 mg/kg) and achieved a near-complete response ( Figures 1A, B ). The patient responded quickly and remarkably to this combination with a near-complete regression of the liver metastases ( Figures 1C, D ). The disease and treatment timeline is provided in  Figure 1E .